{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:00:11Z","timestamp":1772769611604,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.mayocp.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T04:46:31Z","timestamp":1665117991000},"page":"2099-2106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6069-1507","authenticated-orcid":false,"given":"Chi D.","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil R.","family":"Powe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian E.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine S.","family":"Tuot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mayocp.2022.07.010_bib1","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/ndt\/gfq792","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials","volume":"26","author":"Maione","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.mayocp.2022.07.010_bib2","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.07.010_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1161\/HYPERTENSIONAHA.120.16281","article-title":"Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria","volume":"77","author":"Chu","year":"2021","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.mayocp.2022.07.010_bib4","doi-asserted-by":"crossref","first-page":"e2127014","DOI":"10.1001\/jamanetworkopen.2021.27014","article-title":"Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in chronic kidney disease care in the US by race and ethnicity, 2012-2019","volume":"4","author":"Chu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.mayocp.2022.07.010_bib5","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.mayocp.2020.12.038","article-title":"Barriers to ACEI\/ARB use in proteinuric chronic kidney disease: an observational study","volume":"96","author":"McCoy","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"4S","key":"10.1016\/j.mayocp.2022.07.010_bib6","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"issue":"3S","key":"10.1016\/j.mayocp.2022.07.010_bib7","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocp.2022.07.010_bib8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.mayocp.2022.07.010_bib9","doi-asserted-by":"crossref","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"Linde","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"15","key":"10.1016\/j.mayocp.2022.07.010_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2022.07.010_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11, suppl","key":"10.1016\/j.mayocp.2022.07.010_bib12","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.mayocp.2022.07.010_bib13","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"19","key":"10.1016\/j.mayocp.2022.07.010_bib14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2022.07.010_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein\u2013creatinine ratio or urine dipstick protein to urine albumin\u2013creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant\u2013based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.mayocp.2022.07.010_bib16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A\u00a0predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2022.07.010_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis [published correction appears in JAMA. 2016;315(8):822","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2022.07.010_bib18","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.mayocp.2022.07.010_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-016-0663-4","article-title":"New agents in treatment of hyperkalemia: an opportunity to optimize use of RAAS inhibitors for blood pressure control and organ protection in patients with chronic kidney disease","volume":"18","author":"Rastogi","year":"2016","journal-title":"Curr Hypertens Rep"},{"issue":"9","key":"10.1016\/j.mayocp.2022.07.010_bib20","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622004475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622004475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:56:32Z","timestamp":1706003792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622004475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0025619622004475"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.07.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}